KRAS and neoplasm: We hypothesized that KRAS mutation-positivity in resection or venous margins from patients receiving neoadjuvant therapy with good ypT0N0R0 pathological response and longer survival would be lower to undetectable, as compared to samples from resection and venous margins of up-front surgery R0 tumours, with shorter survival.